Transverse colon samples from confirmed Alzheimer’s disease cases showed distinct gut microbiome and proteomic shifts, ...

Alzheimer's disease is a multifactorial neurodegenerative disorder, characterized by amyloid plaques, neurofibrillary tangles, and gliosis. Beyond genetic and age-related factors, diverse risk ...

More than half of 95 centenarians had a low amyloid load and 9% had no amyloid, autopsy data showed. A third of centenarians had a high amyloid load comparable to Alzheimer's disease. Five ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related to Alzheimer's disease in individuals with mild cognitive impairment (MCI) ...

Findings showed testing with Elecsys pTau181 helped to rule out Alzheimer pathology with a 97.9% negative predictive value in this early disease-stage population. The Food and Drug Administration (FDA ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) ...

A biomarker test identified tau pathology in Alzheimer's disease before fibrillary tangles developed. Neurofibrillary tangle formation can be prevented by targeting intermediate soluble tau assemblies ...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is highlighting a peer-reviewed study that independently ...